MGC Pharmaceuticals Reports Solid Growth in October

MGC Pharmaceuticals Ltd (ASX: MXC) has reported that the number of patients being prescribed its cannabinoid medicines has now passed the key milestone of 600 in Australia & the United Kingdom.

  • Prescriptions were 400 at the end of September.
  • Average 19 prescriptions issued per day to date in October.
  • MXC is working closely with distributors to onboard further clinics.

By 12:39 PM AEST, MXC was quoting at $0.036, up by 5.9% from the last close.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report